Home » Halozyme and Baxter Expand Relationship
Halozyme and Baxter Expand Relationship
April 1, 2005
Halozyme Therapeutics, a development stage biopharmaceutical company focused on the development and commercialization of recombinant human enzymes, and Baxter Healthcare Corporation announced that they have expanded their relationship by signing a development and supply agreement for Enhanze SC, Halozyme's recombinant human hyaluronidase enzyme (rHuPH20).
BioSpace (http://www.biospace.com/news_story.cfm?StoryID=19545820&full=1)
(http://www.biospace.com/news_story.cfm?StoryID=19545820&full=1)
KEYWORDS FDAnews Drug Daily Bulletin
Upcoming Events
-
21Oct